5 min

Ipilimumab as adjuvant therapy improves OS in high risk melanoma ESMO 2016

    • Medicine

Prof Eggermont speaks with ecancertv at ESMO 2016 about results from the EORTC 18071 phase III trial of ipilimumab, an anti-CTLA 4 immune checkpoint inhibitor, as an adjuvant therapy for patients with high risk stage III melanoma.

Prof Eggermont describes the improved overall survival rate of five years, 11% high in the ipilumumab arm, as coming at the cost of immune related side effects associated with ipilimumab.

Prof Eggermont speaks with ecancertv at ESMO 2016 about results from the EORTC 18071 phase III trial of ipilimumab, an anti-CTLA 4 immune checkpoint inhibitor, as an adjuvant therapy for patients with high risk stage III melanoma.

Prof Eggermont describes the improved overall survival rate of five years, 11% high in the ipilumumab arm, as coming at the cost of immune related side effects associated with ipilimumab.

5 min

Top Podcasts In Medicine

More by ecancer